SMR3B

Across TCGA pan-cancer cohorts, SMR3B RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SMR3B’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where SMR3B RNA is repressed in tumor relative to normal tissue. In most cancer types SMR3B is over-expressed in tumor, although a few such as HNSC and BRCA show the opposite, repressed pattern.

HNSC, BRCA, and PRAD are the cancer types where SMR3B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SMR3B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	II,III,IV	−3.807	<.001	8	view →
BRCA	Female	All	−0.980	<.001	8	view →
PRAD	All	All	−1.306	<.001	2	view →
THCA	Male	II,III,IV	−0.720	.018	2	view →
UCEC	All	All	+0.228	.035	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

SMR3B–HNSC

Open the HNSC breakdown →